Company
NewcelX Ltd. (NCEL)
Standardized SEC financial data for NewcelX Ltd. — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0001783036 · NASDAQ · Pharmaceutical Preparations.
Return on equity
-114.5%
ROIC
-39.2%
Free cash flow
-$2.8M
Debt / equity
0.02×
Current ratio
0.76×
EPS (diluted)
$2.16
Income statement
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| R&D expense | $100K | $5.9M | $9.0M | $1.6M | $992K | $1.1M |
| SG&A expense |
Balance sheet
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $94K | $5.4M | $8.9M | $1.3M | $650K | $2.2M |
| Total current assets |
Cash flow
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$729K | -$14.9M | -$13.9M | -$3.4M | -$1.1M | -$2.8M |
| Capital expenditures |
Get NCEL data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/NCEL/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/NCEL/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"